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Abstract Vascular endothelial growth factor (VEGF) stimu-
lated a time- and concentration-dependent increase in PGI2
synthesis in human umbilical vein endothelial cells with a mean
maximum increase of 2-fold above basal levels at 25 ng/ml after
60 min. VEGF also rapidly stimulated the release of arachidonic
acid and phosphorylation and activation of cytosolic phospho-
lipase A2 (cPLA2). The VEGF-related factor, placenta growth
factor (PlGF), had little effect on PGI2 synthesis, arachidonic
acid release or cPLA2 activation. PD98059, a selective inhibitor
of MAP kinase kinase, caused complete inhibition of VEGF-
stimulated MAP kinase activity, PGI2 synthesis and cPLA2 gel
retardation, but had no effect on VEGF-induced vWF secretion.
These findings provide the first evidence that VEGF can
stimulate PGI2 synthesis via cPLA2-mediated arachidonic acid
release and indicate that VEGF stimulation of this biosynthetic
pathway may occur, at least in part, via activation of p42/p44
MAP kinases.
z 1997 Federation of European Biochemical Societies.
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1. Introduction
The endothelium of the arterial wall releases a variety of
factors which play essential roles in the control of vascular
tone and reactivity [1,2]. One of these factors, the prostanoid
PGI2, is an important regulator of vascular functions includ-
ing vasodilatation, platelet aggregation, vascular permeability
and vascular smooth muscle cell (VSMC) proliferation [3,4].
PGI2 production is stimulated in cultured endothelial cells by
a variety of agonists acting through receptors with seven
transmembrane domains coupled to G-proteins, including
thrombin, histamine, ATP and bradykinin [5^7]. In contrast
to the well-established e¡ects of agonists for G-protein
coupled receptors, there have been few reports of endothelial
PGI2 production in response either to cytokines or polypep-
tide growth factors for receptor protein tyrosine kinases.
A major pathway leading to PGI2 synthesis results from
agonist-induced activation of the cytosolic form of PLA2
(cPLA2), the release of arachidonic acid from membrane
phospholipids and its conversion into PGI2 via cyclooxygen-
ase and PGI synthase [8^10]. Recent evidence shows that
thrombin-stimulated activation of cPLA2 and PGI2 synthesis
involves phosphorylation by members of the mitogen-acti-
vated protein (MAP) kinase family, including p42/p44 Erks
[11^13] and p38 MAP kinase [14^16].
The 46 kDa secreted polypeptide factor, vascular endothe-
lial growth factor (VEGF) plays an essential role in angio-
genesis in vivo [17]. VEGF expression is upregulated by hy-
poxia and by cytokines and growth factors in arterial vascular
smooth muscle cells (VSMC) [18,19] and recent ¢ndings sug-
gest that VEGF may have a role in maintaining normal vas-
cular function and inhibiting VSMC proliferation in vivo [20^
25]. In particular, VEGF gene transfer inhibits intimal VSMC
proliferation in models of arterial neo-intima formation [22^
25] but the mechanism(s) involved in this e¡ect are not clearly
understood. The biological e¡ects of VEGF are mediated by
two protein tyrosine kinase receptors, the fms-like tyrosine
kinase, Flt-1, and KDR/Flk-1 [26,27]. VEGF exhibits high-
a⁄nity binding to both receptors, and the closely related fac-
tor, placental growth factor (PlGF), is a speci¢c ligand for
Flt-1 and does not bind to KDR/Flk-1 [28].
In the present paper we show that VEGF induces PGI2
generation via activation of cPLA2. Further, we present evi-
dence that PGI2 production induced by VEGF is mediated by
the MAP kinase pathway. These ¢ndings suggest one impor-
tant mechanism by which vascular protective actions of this
factor may be mediated.
2. Materials and methods
2.1. Cell culture
HUVECs were obtained from fresh umbilical cords by collagenase
digestion and cultured on 1% gelatin-coated plates in medium 199
(M199) supplemented with 20% fetal calf serum and endothelial cell
growth supplement [29]. Cells were used after 6^8 days or when the
cells had formed a con£uent monolayer.
2.2. PGI2 assay
HUVECs were washed twice in serum-free M199 (pH 7.4) and after
treatments the PGI2 content of cell supernatants was quanti¢ed by
radioimmunoassay of 6-keto PGF1K, the stable breakdown product of
PGI2 as described [30].
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2.3. Arachidonic acid release
Arachidonic acid release was determined essentially as described
[31]. Con£uent HUVEC cultures were incubated for 24 h with
[5,6,8,9,11,12,14,15-3H]arachidonic acid (1 mCi/ml, 211 Ci/mmol).
The cells were then washed twice with M199 and incubated in 1 ml
of this medium supplemented with 0.3% BSA (essential fatty acid free)
and other additions as indicated. The medium was then removed,
centrifuged at 16000Ug for 5 min, and the radioactivity in the super-
natant was determined by counting in a scintillation counter.
2.4. Western blotting procedures
Assays of MAP kinase activity and cPLA2 activation were per-
formed by Western blotting of whole cell extracts using, respectively,
an antibody which speci¢cally recognizes p42 and p44 MAP kinases
(Erk-1 and Erk-2) activated by phosphorylation at Tyr204 [32] and a
polyclonal antiserum to cPLA2 [15,16]. Immunoreactive bands were
visualized by chemiluminescence using HRP-conjugated anti-mouse or
anti-rabbit IgG and ECL reagent.
2.5. Assay of vWF secretion
vWF secretion was measured by ELISA as described [30] in samples
of medium obtained from con£uent cultures of HUVECs which had
been treated with factors, as indicated. Plates were coated with the
anti-vWF mAb CLBRAg35, and the lower detection limit of the assay
was approximately 1.0 mU/ml.
2.6. Materials
Recombinant VEGF was obtained from RpD Systems. Recombi-
nant PIGF was the gift of Professor Werner Risau and was also
obtained from RpD Systems. Polyclonal cPLA2 antiserum was the
gift of Dr. Ruth Kramer (Eli Lilly, Indianapolis, IN). The anti-vWF
mAb CLBRAg35 was the gift of Dr. J.A. Van Mourik (Central Blood
Laboratory, Amsterdam, The Netherlands). Antibody to the activated
phosphorylated form of p42/p44 MAP kinase was purchased from
New England Biolabs Inc. [5,6,8,9,11,12,14,15-3H]arachidonic acid,
ECL reagents and HRP-conjugated anti-mouse IgG were from Amer-
sham, UK. Goat anti-rabbit HRP-conjugated IgG was from Pierce
Inc. Other reagents used were of the purest grade available.
3. Results
Con£uent cultures of HUVEC were treated for various
times up to 2 h with VEGF and the medium was removed
and assayed for 6-keto PGF1K, a stable metabolic breakdown
product of PGI2. As shown in Fig. 1A VEGF caused a time-
dependent increase in the production of PGI2 which was de-
tectable as early as 15 min after addition of the factor, con-
tinued to increase for up to 60 min, and was sustained for up
to 2 h (Fig. 1A). VEGF stimulation of PGI2 production was
also concentration-dependent. After a 60 min incubation, an
increase in PGI2 synthesis was detectable at 5 ng/ml, was half-
maximal at 10 ng/ml and reached a maximum at 15 ng/ml. It
was consistently noted that VEGF-induced PGI2 synthesis
underwent a small decline at 25 ng/ml (Fig. 1B).
The e¡ect of VEGF was weaker than that of thrombin, a
potent inducer of PGI2 synthesis and PIGF, a speci¢c ligand
for the Flt-1 receptor [28], induced a much weaker stimulation
of PGI2 synthesis compared to VEGF. The mean fold in-
creases in 6-keto PGF1K produced by 60 min incubations
with 25 ng/ml VEGF, 60 ng/ml PlGF and 1 U/ml thrombin
were, respectively, 2.0-, 1.3- and 4.4-fold above the mean con-
trol unstimulated level.
To examine the e¡ect of VEGF on the mobilization of
arachidonic acid, HUVECs were preincubated with radiola-
belled arachidonic acid for 24 h and challenged with VEGF
for di¡erent times. Arachidonic acid release experiments were
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Fig. 1. VEGF-induced PGI2 synthesis and arachidonic acid release in HUVEC. A and B: HUVECs were incubated in the absence (open
circles) or presence (closed circles) of 25 ng/ml VEGF for the times indicated (A) or in the presence of di¡erent concentrations of VEGF for
60 min (B). 6-keto PGF1K was assayed as described. The results shown are representative of three experiments. Values are presented as the
mean þ S.E.M. of 3^4 determinations. C and D: Cells prelabelled with [3H]arachidonic acid were incubated for di¡erent times (C) with 1.0 U/
ml thrombin (closed circles) or 25 ng/ml VEGF (closed triangles) or without addition. The concentration-dependence for VEGF (60 min incu-
bation) is shown in D. The results shown are representative of three experiments and values are presented as the mean þ S.E.M. of triplicate de-
terminations.
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conducted in the presence of 0.3% BSA which binds avidly to
the free fatty acid and acts as a extracellular ‘trap’ for arach-
idonic acid. As shown in Fig. 1C, VEGF caused an increase in
label released into the medium of prelabelled cells which was
evident at 10 min and reached a maximum at 30 min, after
addition of the factor. As measured in parallel cultures, the
time-course for VEGF-stimulated arachidonic acid release
was very similar to that for thrombin (Fig. 1C). The concen-
tration-dependence for VEGF-stimulated arachidonic acid re-
lease was very similar to that obtained for PGI2 production,
with a half-maximal e¡ect at 2.5^5 ng/ml and a maximum at
10^20 ng/ml (Fig. 1D). Similar to the relative abilities of
thrombin and VEGF to stimulate PGI2 production, maxi-
mum VEGF-induced arachidonic acid release was consistently
lower than that obtained for thrombin. In four experiments,
VEGF and thrombin caused mean increases in the release of
labelled arachidonic acid of 1.6- and 3.4-fold above the basal
unstimulated level, respectively. PlGF caused no detectable
increase in arachidonic acid release.
The conversion of cPLA2 to its activated form can be moni-
tored by a shift in its mobility in SDS-PAGE gels from a fast-
to a slow-migrating form [15,16]. In Western blots of extracts
of control HUVECs, antibody to cPLA2 recognized two dis-
tinct bands of approximately equal intensity and migrating
with approximate Mr 97 000 (Fig. 3). Though cPLA2 has a
predicted molecular weight of 85 kDa, this protein has pre-
viously been reported to migrate in SDS-PAGE as a 97 kDa
band [15,16]. VEGF at 25 ng/ml caused a marked increase in
the immunoreactivity of the slow-migrating form of cPLA2
and a concomitant relative decrease in the faster-migrating
form, which was detectable after 2 min, reached a maximum
after 15 min, and was sustained for up to 60 min after VEGF
addition (Fig. 2, upper panel). In ¢ve independent experi-
ments, VEGF consistently caused a marked increase in the
immunoreactivity of the slower-migrating form of cPLA2.
The VEGF-induced decrease in the electrophoretic mobility
of cPLA2 was also concentration-dependent with a noticeable
increase in the slow-migrating form at 2.5 ng/ml and a max-
imum increase at 5^10 ng/ml, the highest concentration tested
(Fig. 2, middle panel). Thrombin also caused a striking shift
in the mobility of cPLA2 from a faster- to a slower-migrating
form and, similar to the results obtained for PGI2 synthesis
and arachidonic acid release, the e¡ect of thrombin was great-
er than that of VEGF with virtually complete disappearance
of the faster-migrating form of the enzyme (Fig. 2, middle
panel). PlGF caused no detectable shift in the mobility of
immunoreactive cPLA2 from faster to slower-migrating forms
(results not shown).
It was next investigated whether VEGF-induced PGI2 syn-
thesis and cPLA2 activation were mediated via activation of
p42/p44 MAP kinases. We have previously reported that
VEGF induces MAP kinase activation in HUVECs [29].
VEGF induced a detectable increase in activity of p42/p44
MAP kinases in con£uent HUVEC at a concentration as
low as 0.5 ng/ml, a half-maximal increase between 1 and 5
ng/ml, and a maximum e¡ect at 10 ng/ml (results not shown).
PlGF in the concentration range 1^60 ng/ml caused no sig-
ni¢cant increase in MAP kinase activity in HUVEC (results
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Fig. 3. E¡ects of PD98059 on PGI2 synthesis and vWF secretion in-
duced by VEGF and thrombin. HUVEC were pre-treated for 30
min with the indicated concentrations of PD98059 (A) or in the ab-
sence (3) or presence (+) of 25 WM PD98059 (B) and subsequently
incubated as indicated with 25 ng/ml VEGF or 1.0 U/ml thrombin
for 60 min. Assays for 6-keto PGF1K content (A) or vWF content
(B) were as described. The results shown are representative of three
similar experiments. Data are given as mean þ S.E.M. of triplicate
determinations.
Fig. 2. E¡ect of VEGF treatment on mobility of cPLA2 in SDS-
PAGE. HUVECs were incubated in the presence of 25 ng/ml
VEGF for the times indicated (upper) or in the presence of the indi-
cated concentrations of VEGF for 60 min, or with 1.0 U/ml throm-
bin (T) for 20 min (centre). In other experiments (bottom) cells
were pretreated as indicated for 30 min with 25 WM PD98059 and
then incubated with 25 ng/ml VEGF for 15 min as indicated.
Whole-cell lysates were Western blotted using an anti-cPLA2 antise-
rum. The positions of molecular weight markers (MrU1033) and of
phosphorylated (cPLA2-P) and faster-migrating (cPLA2) forms of
cPLA2 are indicated. The results shown are representative of 2^3 ex-
periments.
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not shown). In accord with our previous ¢ndings [29], VEGF
stimulation of p42/p44 MAP kinases was completely inhibited
by a 30 min pretreatment with 10 WM PD98059, a selective
inhibitor of MAP kinase kinase [33], the dual-speci¢city threo-
nine and tyrosine kinase which speci¢cally phosphorylates and
activates p42/p44 MAP kinases. As shown in Fig. 2, pretreat-
ment with PD98059 at 25 WM completely blocked the VEGF-
stimulated increase in the slow-migrating form of cPLA2. It
was noted that the inhibitor not only reversed the VEGF-
dependent decrease in cPLA2 gel mobility, but also decreased
the immunoreactivity of the slower-migrating form below, and
increased that of the faster-migrating form above control
levels.
Pretreatment of HUVEC with 30 WM PD98059 for 30 min
completely inhibited PGI2 production induced by a subse-
quent 60 min incubation with either 25 ng/ml VEGF or 1 U/
ml thrombin (Fig. 3A). The e¡ect of PD98059 on VEGF-
induced PGI2 synthesis was concentration-dependent with a
half-maximal e¡ect at approximately 5 WM and a maximum
inhibitory e¡ect on stimulated PGI2 production at 10 WM
(Fig. 3A). This correlated closely with the concentration-de-
pendence for the e¡ect of the inhibitor on VEGF-stimulated
MAP kinase activity (results not shown). It was also noted
that PD98059 reduced PGI2 production in VEGF-treated cells
to below the values measured in control cells, though this
e¡ect was only apparent at concentrations of the inhibitor
greater than 10 WM (Fig. 3A). VEGF induced a striking in-
crease in vWF secretion (Fig. 3B) which was concentration-
and time-dependent (results not shown). In contrast to its
e¡ect on cPLA2 activation and PGI2 synthesis, pretreatment
of HUVECs with the inhibitor at 25 WM had no e¡ect on
vWF secretion caused by a subsequent addition of either
VEGF or thrombin (Fig. 3B).
4. Discussion
The results presented here show that VEGF stimulates a
striking time- and concentration-dependent increase in PGI2
production in HUVEC. We also show for the ¢rst time that
VEGF stimulates the rapid mobilization of arachidonic acid
from human endothelial cells and, as judged by a gel retarda-
tion assay, the rapid activation of cPLA2. The concentration-
dependencies for VEGF-induced PGI2 production, arachi-
donic acid release and cPLA2 activation were similar to
each other (all within the range 5^10 ng/ml) and are also
similar to the concentration-dependence reported for the ef-
fects of VEGF on mitogenesis, chemotaxis and other early
signalling events in HUVECs [29,34]. These results indicate
that VEGF stimulation of arachidonic acid release and
PGI2 synthesis are mediated through high-a⁄nity receptors
for this factor in HUVECs. Since PlGF induced PGI2 syn-
thesis more weakly than VEGF and also failed to signi¢cantly
increase either arachidonic acid release or cPLA2 mobility
shift, these results are most consistent with the conclusion
that stimulation of PGI2 production by VEGF in HUVECs
is mediated primarily by KDR/Flk-1 receptors.
Recent ¢ndings have implicated the p42/p44 MAP kinases
in the phosphorylation and activation of cPLA2. The ¢nding
that VEGF causes a rapid shift in the electrophoretic mobility
of cPLA2 is most consistent with increased phosphorylation,
and hence activation, of the enzyme. This inference is sup-
ported by the ¢nding that thrombin, which is known to stim-
ulate cPLA2 phosphorylation and activation in platelets
[15,16], caused a similar shift in cPLA2 mobility in HUVECs.
The results presented here also show that VEGF activates
p42/p44 MAP kinases and that inhibition of this pathway
with a selective inhibitor of MAP kinase kinase, PD98059,
blocks PGI2 production and the increased gel retardation of
cPLA2 induced by VEGF. PD98059 was previously reported
to block thrombin-induced PGI2 production in HUVECs [13].
Though it is impossible to preclude non-speci¢c e¡ects of the
inhibitor, the e¡ect of PD98059 was at least partially selective
since it had no e¡ect on vWF secretion stimulated either by
VEGF or by thrombin. Furthermore, the inhibitory e¡ect of
PD98059 on PGI2 synthesis could be reversed by addition of
exogenous arachidonic acid to the cells (results not shown).
Compared to the e¡ect of the potent inducer of p38 kinase
activator, anisomycin, VEGF did not signi¢cantly increase
p38 kinase activity in HUVECs (results not shown) suggesting
that p38 kinase is unlikely to play a major role in VEGF-
induced cPLA2 activation. It is plausible that other signalling
mechanisms may contribute to VEGF stimulation of PGI2
synthesis and arachidonic acid release, including elevation of
intracellular Ca2. cPLA2 is sensitive to physiological Ca2
concentrations [8] and VEGF is able to induce the mobiliza-
tion of Ca2 from intracellular stores [26,27,35]. Since the
Ca2 ionophore ionomycin can stimulate PGI2 synthesis in
HUVECs without activating the MAP kinase pathway
(C.J.W. Wheeler-Jones et al., unpublished results), any
Ca2-dependent e¡ect of VEGF is likely to occur independ-
ently of the MAP kinase-dependent pathway. The ¢nding that
a MAP kinase kinase inhibitor blocks VEGF-stimulated PGI2
synthesis but does not a¡ect vWF secretion suggests that these
two biological responses to VEGF are triggered by distinct
intracellular signalling pathways. The precise relationship be-
tween Ca2 £uxes, MAP kinase activation and PGI2 synthesis
in the action of VEGF requires more detailed delineation.
The mechanisms involved in VEGF-dependent inhibition of
intimal VSMC hyperplasia are unclear but have been pro-
posed to be primarily due to the stimulation of endothelial
re-growth. Given that prostanoid-stimulated elevation of in-
tracellular cyclic AMP is a potent inhibitor of VSMC mito-
genesis [2], it is attractive to hypothesize that VEGF stimula-
tion of PGI2 has other biological e¡ects in the vascular
system, including vasodilatation, increased vascular perme-
ability and the inhibition of platelet aggregation [4^6], and
it is entirely possible that VEGF-induced PGI2 production
may have implications for the regulation of other aspects of
vascular reactivity. For example, the reported e¡ects of VEGF
on vasodilatation of blood vessels [21,22] may be mediated in
part by PGI2.
The ¢nding that VEGF stimulates PGI2 production, arach-
idonic acid mobilization and cPLA2 activation probably
through a MAP kinase-dependent pathway identi¢es both a
novel function and a new mechanism of action for VEGF in
endothelial cells. Activation of this pathway by VEGF is con-
sistent with a role for this factor in the protection of the intact
vessel wall. The ability of VEGF both to augment endothelial
cell responses and to promote endothelial regeneration makes
this factor ideally suited for a role in the maintenance and
renewal of normal blood vessel functions.
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